Boston Scientific Falls Short of Projected $150M in Q207
July 20, 2007 – Despite forecasts by analysts at Thomson Financial that Boston Scientific Corp. would earn $150 million in the second quarter of this year, the company came up short at $115 million in the second quarter, or 7.7 cents a share, due to a significant sales slump in implantable defibrillators and coronary stents.
In 2006, Boston Scientific reported a $4.3 billion loss from its April 2006 purchase of Guidant Corp. Excluding special charges related to the acquisition, the company's profit fell 56 percent from the second quarter of 2006.
More like this
- Boston Scientific Decides Not to Sell Surgical Device Unit
- Boston Scientific Offers PROMUS Everolimus-Eluting Coronary Stent System
- Boston Scientific Releases Drug-Eluting Stent Market Share Estimates For September, Third Quarter
- Courts Decide on Boston Scientific, Johnson & Johnson Stent Patent Disputes
- New CRT-D, ICD Implants Treat Heart Failure, CAD